Cargando…

Risk Analysis by Age on the Burden of Meningococcal Disease in Spain

We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivero-Calle, Irene, Raguindin, Peter Francis, Pardo-Seco, Jacobo, Martinon-Torres, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026321/
https://www.ncbi.nlm.nih.gov/pubmed/35455341
http://dx.doi.org/10.3390/vaccines10040592
_version_ 1784691094981705728
author Rivero-Calle, Irene
Raguindin, Peter Francis
Pardo-Seco, Jacobo
Martinon-Torres, Federico
author_facet Rivero-Calle, Irene
Raguindin, Peter Francis
Pardo-Seco, Jacobo
Martinon-Torres, Federico
author_sort Rivero-Calle, Irene
collection PubMed
description We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing the hospitalization rate. We computed the odds ratio of each age using <1 year old as a reference group. From 1998 to 2017, 13,554 hospitalized cases were diagnosed, with a declining trend across the years. Infants (<1 year, n = 2425) and children (1–14 years, n = 6053) comprised the majority of all hospitalized meningococcal disease in Spain (62.5% or 8474/13,554). The incidence of hospitalization decreased dramatically with age from 56.2/100,000 in <1-year-old children to 1.3/100,000 in >5-year-old children. There was a dramatic decline in risk in 1 year (OR 0.58) to 4 years of age (OR 0.21). The risk continued to decline until 13 years old. Afterward, it had a minimal upward trajectory observed at 14–17 years old (OR 0.08). Infants and adolescents are at continued risk of invasive meningococcal disease in Spain. The highest risk occurs in infants. Surveillance data, together with evidence on long-term immunogenicity and capacity for herd effect, should be considered for a more relevant immunization schedule.
format Online
Article
Text
id pubmed-9026321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90263212022-04-23 Risk Analysis by Age on the Burden of Meningococcal Disease in Spain Rivero-Calle, Irene Raguindin, Peter Francis Pardo-Seco, Jacobo Martinon-Torres, Federico Vaccines (Basel) Article We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing the hospitalization rate. We computed the odds ratio of each age using <1 year old as a reference group. From 1998 to 2017, 13,554 hospitalized cases were diagnosed, with a declining trend across the years. Infants (<1 year, n = 2425) and children (1–14 years, n = 6053) comprised the majority of all hospitalized meningococcal disease in Spain (62.5% or 8474/13,554). The incidence of hospitalization decreased dramatically with age from 56.2/100,000 in <1-year-old children to 1.3/100,000 in >5-year-old children. There was a dramatic decline in risk in 1 year (OR 0.58) to 4 years of age (OR 0.21). The risk continued to decline until 13 years old. Afterward, it had a minimal upward trajectory observed at 14–17 years old (OR 0.08). Infants and adolescents are at continued risk of invasive meningococcal disease in Spain. The highest risk occurs in infants. Surveillance data, together with evidence on long-term immunogenicity and capacity for herd effect, should be considered for a more relevant immunization schedule. MDPI 2022-04-12 /pmc/articles/PMC9026321/ /pubmed/35455341 http://dx.doi.org/10.3390/vaccines10040592 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rivero-Calle, Irene
Raguindin, Peter Francis
Pardo-Seco, Jacobo
Martinon-Torres, Federico
Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
title Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
title_full Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
title_fullStr Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
title_full_unstemmed Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
title_short Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
title_sort risk analysis by age on the burden of meningococcal disease in spain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026321/
https://www.ncbi.nlm.nih.gov/pubmed/35455341
http://dx.doi.org/10.3390/vaccines10040592
work_keys_str_mv AT riverocalleirene riskanalysisbyageontheburdenofmeningococcaldiseaseinspain
AT raguindinpeterfrancis riskanalysisbyageontheburdenofmeningococcaldiseaseinspain
AT pardosecojacobo riskanalysisbyageontheburdenofmeningococcaldiseaseinspain
AT martinontorresfederico riskanalysisbyageontheburdenofmeningococcaldiseaseinspain